Forget crypto winter. In biotech, it's been freezing for months
One exec compares the environment to a hurricane.
Source: moneyweb.co.za
📰 Mark Lappe News
Page 3 - Mark Lappe News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mark Lappe. Real-time updates on events, politics, business and more.
Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today...
Source: prnewswire.com
Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today...
Source: prnewswire.com
Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today...
United States Mark Lappe Bristol Myers Squibb Exchange Commission Prnewswire Inhibrx Inc Drug Administration
Source: prnewswire.com
Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today...
Source: prnewswire.com
Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today...
Source: prnewswire.com
Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today...
United States Mark Lappe Bristol Myers Squibb Exchange Commission European Union Drug Administration
Source: prnewswire.com
Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), announced the appointment of three key executives: David Matly, M.B.A., as Chief Commercial Officer; David Kao,...
Source: prnewswire.com
INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, today...
Source: prnewswire.com
Inhibrx Reports First Quarter 2021 Financial Results
Inhibrx Reports First Quarter 2021 Financial Results News provided by Share this article Share this article SAN DIEGO, May 13, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the first quarter of 2021. "This past quarter, we continued to make significant progress advancing our clinical programs and are on track to deliver data from all four programs later this year," said the Companys Ch...
Source: prnewswire.com